<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58645">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342548</url>
  </required_header>
  <id_info>
    <org_study_id>A8241022</org_study_id>
    <secondary_id>2014-004900-31</secondary_id>
    <secondary_id>OPEN LABEL TO A8241021</secondary_id>
    <nct_id>NCT02342548</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021</brief_title>
  <official_title>An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following
      study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and
      tolerability of 20 mg BID of PF-02545920. Secondary endpoints will be the change from
      baseline in the Total Motor Score (TMS)assessment, and/ior the Total maximum Chorea (TMC)
      assessment of the Unified Huntington Disease Rating Scale (UHDRS) after 6 and 12 months of
      treatment, and Clinical Global Impression-Improvement score after 6 and 12 months of
      treatment. Subjects, who were assigned to the 20 mg PF-02545920 dose group in the preceding
      A8241021 study, will receive 20 mg PF-02545920 without any titration. All other subjects
      will be titrated to the 20 mg BID dose as follows: 5 mg BID for 7 days, 10 mg BID for 7
      days, 15 mg BID for 7 days, then 20 mg BID for the remainder of the treatment phase. Up to
      260 subjects may take part in this open label extension
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated on 15DEC2016 due to study A8241021 showing no significant difference on
    primary endpoint between PF-02545920 &amp; placebo. No safety concerns.
  </why_stopped>
  <start_date type="Actual">February 25, 2015</start_date>
  <completion_date type="Actual">February 6, 2017</completion_date>
  <primary_completion_date type="Actual">February 6, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>White blood count and absolute neutrophil count</measure>
    <time_frame>Baseline to Follow-up visit (Day 365)</time_frame>
    <description>Monitoring of ANC and WBC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extrapyramidal symptoms</measure>
    <time_frame>Baseline to Follow-up visit (Day 365)</time_frame>
    <description>Occurence of dystonia or akathisia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline to Follow-up Visit (Day 365)</time_frame>
    <description>C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of &quot;Yes&quot; on &quot;actual attempt&quot;), preparatory acts toward imminent suicidal behavior (3)(&quot;Yes&quot; on &quot;preparatory acts or behavior&quot;), suicidal ideation (4) (&quot;Yes&quot; on &quot;wish to be dead&quot;, &quot;non-specific active suicidal thoughts&quot;, &quot;active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(&quot;Yes&quot; on &quot;Has subject engaged in non-suicidal self-injurious behavior&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UHDRS Total Motor Score (TMS) after 6 and 12 months of treatment</measure>
    <time_frame>Baseline, 6 months and 12 months of treatment in the Open label</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UHDRS Total Maximum Chorea (TMC) after 6 and 12 months of treatment</measure>
    <time_frame>Baseline, 6 months and 12 months of treatment in the Open label</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in • Clinical Global Impression-Improvement score after 6 and 12 months of treatment</measure>
    <time_frame>Baseline, 6 months and 12 months of treatment in the Open label</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>20 mg BID PF-02545920 non-titrated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg BID PF-02545920 titrated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg BID of PF-02545920</intervention_name>
    <description>All subject who completed A8241021 will receive 20 mg BID (with or without titration)</description>
    <arm_group_label>20 mg BID PF-02545920 non-titrated</arm_group_label>
    <arm_group_label>20mg BID PF-02545920 titrated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have completed study A8241021

          -  Diagnosis of HD, including ≥36 CAG repeats.

        Exclusion Criteria:

          -  Significant neurological disorder other than Huntington's disease.

          -  WBC ≤ 3500/mm3 AND/OR ANC ≤ 2000/mm3 and history of neutropenia or
             myeolo-proliferative disorders.

          -  Any drug related SAE experienced during study A8241021 which were not approved as
             acceptable for enrollment in A8241022.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kirkland Clinic of UAB Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scotsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine (Drug Shipment)</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center Drug Information Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Neurology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Radiology (MRI Location)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Center for Movement Disorders &amp; Neurorestoration</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Neuroscience Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wexner Medical Center at the Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wright Center of lnnovation- The Oho State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre For Huntington Disease, The University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Movement Disorders</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Notre-Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Notre-Dame, Pharmacie</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität zu Lübeck</name>
      <address>
        <city>Lubeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps Universitat Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George-Huntington-Institut</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kbo-Isar-Amper-Klinikum gGmbH</name>
      <address>
        <city>Taufkirchen</city>
        <zip>84416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wuerzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copernicus Podmiot Leczniczy sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakow Akademia Neurologii SP. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solumed Centrum Medyczne</name>
      <address>
        <city>Poznan</city>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii, I Klinika Neurologiczna</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford Road</city>
        <state>Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Nicholas Hospital</name>
      <address>
        <city>Gosforth</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE3 3XT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bimingham &amp; Solihull Mental Health NHS Foundation Trust Department of Neuropsychiatry</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2FG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Grampian, Aberdeen Royal Infirmary, Clinical Genetics Centre</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Psychological Medicine and Clinical Neurosciences</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals Huntington's Diesease</name>
      <address>
        <city>London</city>
        <zip>wc1b 5eh</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Institute for Health Research / Wellcome Trust Clinical Research Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Magnetic Resonance Centre</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospital NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust, Wessex Neurological Centre</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8241022&amp;StudyName=An%20Open%20Label%20Extension%20Study%20To%20Investigate%20The%20Long%20Term%20Safety%2C%20Tolerability%20And%20Efficacy%20Of%20Pf-02545920%20In%20Subjects%20With%20Huntington%E2%80%99s%20Disease%20Who%20Previously%20Completed%20Study%20A8241021</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>January 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington; chorea; total motor score; CAG repeat: total functional capacity; motor cognitive and behavioral symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
